• Alkermes will present psychiatry and sleep research at the Neuroscience Education Institute Fall Congress Nov. 5-8, 2026, in Colorado Springs.
• Investigational alixorexton improved patient-reported cognitive functioning and fatigue in participants with narcolepsy type 1 in the Vibrance-1 study.
• A real-world study assessed acute care events surrounding LYBALVI initiation in patients with schizophrenia or bipolar I disorder with comorbid alcohol use disorder.
• ASPIRE study findings will explore associations between depression and disease burden in adults with narcolepsy or idiopathic hypersomnia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202611050700BIZWIRE_USPR_____20261105_BW104984) on November 05, 2026, and is solely responsible for the information contained therein.